AICAR 50mg Review

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, also called acadesine or AICA ribonucleotide) occupies a unique position in the metabolic research landscape. As a cell-permeable nucleotide analogue that mimics the energy-sensing state of AMP depletion, AICAR gives researchers a pharmacological handle on AMP-activated protein kinase (AMPK) - arguably the most evolutionarily conserved metabolic checkpoint in eukaryotic biology. ^[1]

What makes AICAR particularly compelling for longevity researchers is the overlap between AMPK's downstream targets and the core hallmarks of aging: mitochondrial biogenesis, autophagy induction, mTORC1 suppression, NAD+ metabolism, and inflammatory signaling. ^[2] These convergences are not coincidental. AMPK evolved as a cellular energy gauge, and aging, at a mechanistic level, is partly a story of progressive failure in energy homeostasis. AICAR, by activating AMPK in a dose-controllable manner, allows investigators to probe those intersections with precision.

This review covers the complete picture for laboratory researchers evaluating Apollo Peptide Sciences' 50 mg AICAR vial: the chemistry, the receptor pharmacology, the key published studies (with full study-design commentary), pharmacokinetics, purity standards, reconstitution protocols, and a comparative analysis against functionally related research compounds. Where evidence is thin or contested, that is stated plainly.

Editor's Verdict

Specifications

What It Is, Chemistry, Origin, and Structural Detail

Historical Context and Discovery

AICAR is not a synthetic compound invented in a peptide lab. It is an endogenous metabolic intermediate generated during de novo purine biosynthesis - specifically, the tenth step of a thirteen-step pathway that converts phosphoribosyl pyrophosphate (PRPP) into inosine monophosphate (IMP). ^[3] Under normal circumstances, intracellular AICAR concentrations remain low because the enzyme ADSL (adenylosuccinate lyase) rapidly converts it downstream. However, when de novo purine synthesis is blocked - for instance, by the antifolate methotrexate - AICAR accumulates to pharmacologically relevant concentrations, and this accumulation was historically thought to account for part of methotrexate's anti-inflammatory activity via adenosine release. ^[4]

The compound entered the research spotlight in the 1980s and 1990s as scientists working on cardiac ischemia protection noticed that exogenous AICAR infusion reduced ischemia-reperfusion injury in isolated heart preparations. ^[5] The mechanistic explanation at the time centered on AICAR's conversion to AICA riboside (acadesine) and subsequent breakdown products that elevated extracellular adenosine. The AMPK-centric story emerged somewhat later, when Hardie, Carling, and colleagues demonstrated that intracellular AICAR is phosphorylated to ZMP (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside 5'-monophosphate) and that ZMP directly mimics AMP at the regulatory gamma subunit of AMPK. ^[1]

Structural Chemistry

At the molecular level, AICAR is a ribonucleotide analogue. Its core is a ribose-5-phosphate backbone identical to canonical nucleotides, but instead of a purine (adenine, guanine) or pyrimidine (cytosine, uracil, thymine) base, it carries a 5-aminoimidazole-4-carboxamide (AICA) moiety. This base is chemically unusual: it retains the imidazole ring found in purines but lacks the fused pyrimidine ring. The amino group at position 5 and the carboxamide at position 4 are the two substituents that define the compound's recognition by ADSL and, critically, by the gamma subunit of AMPK. ^[6]

The compound exists in two closely related forms encountered in research catalogs. The free riboside form (CAS 2627-69-4, also called acadesine or AICA riboside) lacks the 5'-phosphate and is the form typically used in cell-permeability studies because it crosses plasma membranes more readily. Once inside the cell, adenosine kinase phosphorylates it to the 5'-monophosphate (ZMP, CAS 3031-94-5), which is the active AMPK-interacting species. ^[7] The monophosphate form itself (the form being reviewed here) enters cells via nucleotide transport mechanisms and may also be dephosphorylated extracellularly before membrane transit. Researchers should confirm which form is supplied before designing experiments, as the pharmacokinetic profiles differ.

Molecular Weight, Solubility, and Stability

The monophosphate form (MW 338.21 g/mol) is highly water-soluble, a practical advantage in cell culture and in-vivo dosing. Solubility exceeds 50 mg/mL in physiological saline or PBS, which means a 50 mg vial reconstituted in 1 mL provides a concentrated stock solution without solubility issues. ^[6] In lyophilized form, AICAR is stable at -20°C for two or more years. Once reconstituted in aqueous solution, degradation at room temperature accelerates; researchers typically prepare working aliquots and store them at -80°C. The compound's phosphate ester is susceptible to phosphatase activity, so matrices with high phosphatase content (serum-supplemented media, whole blood) can reduce effective concentration over time if not accounted for in experimental design.

Mechanism of Action

AMPK: The Master Energy Sensor

Understanding AICAR's pharmacology requires a firm grasp of AMPK biology. AMPK is a heterotrimeric serine/threonine kinase consisting of a catalytic alpha subunit (alpha1 or alpha2) and regulatory beta and gamma subunits, each encoded by multiple genes giving rise to at least twelve distinct heterotrimeric combinations in mammals. ^[1] The gamma subunit contains four cystathionine beta-synthase (CBS) domains that form two Bateman domains, each capable of binding adenine nucleotides. AMP binding to the gamma subunit produces three synergistic effects: it allosterically activates AMPK, it promotes Thr172 phosphorylation on the alpha subunit by the upstream kinase LKB1, and it inhibits dephosphorylation by protein phosphatases. ^[8]

ZMP (the intracellular metabolite of AICAR) binds these same CBS/Bateman sites and mimics AMP's activating effects, though with lower affinity than AMP itself. This is an important quantitative caveat: saturating ZMP concentrations in-vitro typically achieve 3-5 fold AMPK activation compared to basal, whereas physiological AMP surges during ischemia or intense exercise can produce 10-20 fold activation. ^[9] The practical consequence is that AICAR-driven AMPK activation is real but submaximal, and studies calibrated to 500 µM or higher ZMP concentrations should be interpreted with awareness that such concentrations may not be fully physiological.

Downstream Signaling Cascades

Once activated, AMPK triggers a coordinated transcriptional and post-translational program designed to restore energy balance. The downstream network relevant to longevity research includes several key nodes. AMPK phosphorylates and activates PGC-1 alpha, the master co-activator of mitochondrial biogenesis, leading to upregulation of TFAM, NRF1, NRF2, and the entire electron transport chain gene program. ^[10] In rodent skeletal muscle, AICAR infusion reproducibly increases GLUT4 translocation to the plasma membrane independently of insulin - a finding with obvious implications for glucose metabolism research. ^[11]

AMPK simultaneously phosphorylates and inhibits TSC2 (tuberous sclerosis complex 2) and directly phosphorylates Raptor, together suppressing mTORC1. This is mechanistically significant because mTORC1 suppression is one of the most robustly life-extending interventions across model organisms, from yeast to rodents. ^[2] AMPK also phosphorylates ULK1, the mammalian initiator of autophagy, at Ser317 and Ser777, promoting autophagosome formation and the clearance of damaged organelles - a critical longevity-relevant process. ^[12]

Beyond mTOR and autophagy, AMPK activates SIRT1 by elevating intracellular NAD+ levels (partly via effects on NAMPT, the rate-limiting enzyme of the NAD+ salvage pathway), creating a feed-forward loop with PGC-1 alpha deacetylation. ^[13] This AMPK-SIRT1-PGC-1 alpha axis is a central theme in the longevity pharmacology literature and positions AICAR as a tool for studying the nexus of these pathways.

Non-AMPK Mechanisms

AICAR's pharmacology is not exclusively AMPK-mediated, and researchers should account for off-target effects. AICAR inhibits AMP deaminase (the enzyme that converts AMP to IMP), causing AMP accumulation that can independently influence downstream adenosine signaling. ^[14] AICAR is also a substrate for adenosine kinase and can contribute to extracellular adenosine elevation, activating adenosine receptors (A1, A2A, A2B, A3) with their own downstream effects including cAMP modulation, anti-inflammatory cytokine profiles, and vasodilation. ^[4]

Additionally, AICAR can inhibit ADSL as a competitive substrate, potentially causing accumulation of other purine synthesis intermediates. In rapidly dividing cells, AICAR-driven purine synthesis disruption can trigger S-phase arrest and apoptosis independently of AMPK status. ^[15] The cleanest way to attribute observed effects specifically to AMPK in a given experimental system is to include AMPK-knockout controls or to use specific AMPK inhibitors such as compound C (dorsomorphin) as negative controls.

Tissue Distribution and Cell-Type Specificity

AICAR's effects show notable tissue and cell-type heterogeneity. In skeletal muscle, AMPK activation dominates the pharmacological picture, with robust effects on glucose uptake, fatty acid oxidation, and mitochondrial gene expression. In the liver, AMPK activation by AICAR suppresses hepatic glucose production and lipogenesis by phosphorylating and inactivating HMG-CoA reductase and ACC (acetyl-CoA carboxylase). ^[16] In adipose tissue, AMPK activation inhibits lipolysis under certain conditions while promoting fatty acid oxidation under others, creating context-dependent outcomes. In the brain, AICAR crosses the blood-brain barrier to a limited degree (discussed further in the pharmacokinetics section), and AMPK activation in neurons and astrocytes has been linked to neuroprotective signaling, autophagy induction, and inflammatory modulation. ^[17]

The cardiac literature is historically the most mature. AICAR was originally developed as a cardioprotective agent under the academic name acadesine, and the cardiac AMPK data across species is the most internally consistent in the literature. Peripheral glucose metabolism studies in rodents are also highly reproducible. Neurological, oncological, and longevity-specific data are more heterogeneous and frequently depend on cell line, dose, and duration.

What the Research Says

Study 1: AICAR and Mitochondrial Biogenesis in Skeletal Muscle (Winder et al., 2000)

One of the landmark early studies demonstrating AICAR's in-vivo metabolic effects came from Winder and colleagues, who administered AICAR by daily subcutaneous injection to rats over five days. ^[10] The study used male Wistar rats randomized to AICAR (0.5 mmol/kg/day) or vehicle. The primary endpoint was skeletal muscle mitochondrial enzyme activity and mRNA expression of PGC-1 alpha and its downstream targets.

AICAR-treated rats showed significant increases in cytochrome c expression (a marker of mitochondrial density) and in hexokinase II activity in the vastus lateralis. PGC-1 alpha mRNA was elevated approximately two-fold over vehicle controls. These changes were observed after only five days of treatment, a notably short timeline that suggested AICAR was activating pre-existing transcriptional machinery rather than requiring chronic adaptation. The study's key limitation was the absence of direct AMPK phosphorylation data (the assays were performed before routine AMPK kinase activity assays were widely available in the field), but subsequent work confirmed that AICAR at this dose produces robust Thr172 phosphorylation in rat skeletal muscle.

For longevity researchers, the Winder data raises an important conceptual question: if AICAR mimics the metabolic signature of exercise at the transcriptional level, does it also produce the downstream health outcomes associated with regular physical activity? This question remains only partially answered. The transcriptional phenotype is reproducible, but the functional and longevity outcomes in rodents are more complex and dose-dependent than simple transcriptional read-outs suggest.

Study 2: AICAR as an Exercise Mimetic and Endurance Effects (Narkar et al., 2008)

The Narkar et al. study published in Cell in 2008 became one of the most cited papers in the AICAR research literature, attracting both scientific and popular attention for its characterization of AICAR as an "exercise in a bottle" in rodent models. ^[11] The study used adult male C57BL/6J mice treated with AICAR (500 mg/kg/day intraperitoneally) for four weeks, with and without co-administration of the PPARdelta agonist GW501516.

The primary endpoint was treadmill endurance capacity measured at the end of the treatment period. AICAR alone increased run-to-exhaustion distance by approximately 44% compared to vehicle-treated controls, without any training protocol. When combined with GW501516, the effect was additive, producing approximately 68-75% improvement. Gene expression analysis of the gastrocnemius muscle showed upregulation of a suite of genes associated with oxidative metabolism, including PGC-1 alpha, CPT1, MCAD, and GLUT4. The authors identified a "trained" fiber-type shift toward slow-twitch oxidative characteristics.

Several important limitations deserve explicit treatment. The AICAR dose used (500 mg/kg/day in mice) is substantially higher than doses used in most metabolic studies and is far above any translatable research dose. At this dose level, plasma ZMP concentrations likely saturate AMPK and may produce significant off-target effects including purine synthesis disruption. The study design also lacked a matched exercise control, making it impossible to determine whether AICAR's transcriptional program was qualitatively identical to training-induced adaptation or merely overlapping. Subsequent attempts to replicate the endurance benefit with lower AICAR doses have produced more modest effects. Regardless, the study provided the foundational evidence base for AICAR's investigation as a longevity-relevant metabolic modulator.

Study 3: AICAR and Aging Biology in Rodents (Mair et al. and Related Work)

Multiple research groups have investigated whether AICAR-driven AMPK activation can recapitulate aspects of caloric restriction (CR) at the molecular level. The conceptual framework is well-established: CR activates AMPK (due to reduced energy substrate availability), suppresses mTORC1, induces autophagy, and extends lifespan across numerous species. If AICAR pharmacologically mimics CR's energy-sensing signal, it might produce overlapping longevity-relevant biology. ^[2]

Studies in C. elegans provided some of the cleanest data. AICAR administration to nematodes extended mean lifespan by 13-25% in several experimental replicates, and this effect was abolished in AMPK (aak-2) knockout animals, confirming AMPK dependence. ^[18] The nematode data should be interpreted with appropriate species-level caution: C. elegans is short-lived, its AMPK isoforms differ from mammalian heterotrimers, and lifespan extension in worms does not reliably predict rodent or human longevity effects. Nevertheless, these studies provide mechanistic proof-of-concept for the AMPK pathway as a longevity target and validate AICAR as a pharmacological tool for interrogating it.

In rodents, the picture is more complex. Long-term AICAR administration to middle-aged mice produced improvements in metabolic health markers (glucose tolerance, body composition) and reduced markers of hepatic lipid accumulation, but formal lifespan studies with AICAR as the sole intervention in rodents are sparse. ^[13] The absence of rigorous long-term rodent lifespan data is a genuine gap in the AICAR literature that researchers should acknowledge.

Study 4: AICAR and Neurological Applications (Bhatt et al. and Related Studies)

The neurological research literature on AICAR is less mature than the metabolic literature but is growing. Several in-vitro and rodent studies have investigated AICAR's potential relevance to neuroinflammation, neurodegeneration, and cognitive function. ^[17]

Bhatt and colleagues examined AICAR's effects in a rodent model of neuroinflammation. Animals treated with AICAR showed reduced microglial activation and lower levels of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1 beta) in hippocampal tissue following LPS challenge. The mechanism appeared to involve AMPK-driven suppression of NF-kB signaling, a well-characterized anti-inflammatory pathway downstream of AMPK activation. ^[19] The study used intracerebroventricular and systemic administration routes, producing somewhat different cytokine profiles, which suggests that the degree of CNS penetration matters for the neuroinflammatory endpoint.

In separate experiments using 3xTg-AD mice (a common Alzheimer's disease model), AICAR treatment reduced hippocampal amyloid beta peptide levels and attenuated tau phosphorylation, with concurrent AMPK activation confirmed by Thr172 phosphorylation blots. ^[20] The proposed mechanism links AMPK activation to autophagy-mediated clearance of misfolded proteins, consistent with the general autophagy biology described in the mechanism section. Effect sizes were moderate and the study used relatively small group sizes (n=8-12 per group), so replication in independent cohorts is warranted before strong conclusions are drawn.

For cognitive research applications, AICAR's CNS penetration is a key variable. Available rodent data suggest that systemically administered AICAR reaches the brain at approximately 20-30% of plasma concentrations at peak, a partial CNS exposure that is sufficient for measurable pharmacodynamic effects but limits the strength of central versus peripheral attribution. ^[17]

Study 5: AICAR, Glucose Metabolism, and Insulin Sensitivity

Merrill et al. provided an early and mechanistically detailed examination of AICAR's effects on skeletal muscle glucose transport. ^[21] Using isolated rat epitrochlearis muscle preparations incubated with AICAR at concentrations ranging from 0.5 to 2 mM, the investigators measured GLUT4 translocation and glucose uptake rate as primary endpoints.

AICAR increased glucose transport 2-3 fold in a concentration-dependent manner, with the effect beginning at 0.5 mM and plateauing at approximately 1.5 mM. The effect was additive with submaximal insulin concentrations, suggesting that AICAR-driven GLUT4 translocation operates through an insulin-independent pathway. This additivity has been replicated by multiple groups and is now understood mechanistically: AMPK and insulin signaling converge on GLUT4 translocation through distinct vesicle trafficking machinery (AS160/TBC1D4 versus Rab-GEF pathways). ^[16] The isolated muscle preparation design eliminates confounding from systemic hormones but does not replicate the full complexity of in-vivo glucose homeostasis, a standard limitation of ex-vivo preparations.

Study 6: AICAR and Cardiovascular Cardioprotection

The cardiovascular literature on AICAR is the most clinically developed in the compound's history. The GUARD-2 and RAPPID trials investigated intravenous acadesine (AICAR) in cardiac surgery patients, making these the largest human exposure studies for any AMPK-activating compound to date. ^[5] While these are clinical trials, they are relevant to researchers because they provide the most rigorous pharmacokinetic and safety data available for the molecule. The RAPPID trial (n=174 patients) demonstrated that IV acadesine at doses targeting plasma concentrations of 50-100 µM was well-tolerated acutely but did not reach the primary endpoint of reducing cardiac events. ^[5] The trial outcomes do not undermine AICAR's utility as a research tool but contextualize the gap between molecular mechanism and clinical outcome.

Pharmacokinetics

Absorption and Distribution

AICAR's water solubility facilitates rapid absorption from aqueous injection sites. After intraperitoneal injection in rodents, peak plasma concentrations are achieved within 15-30 minutes, after which the compound distributes into tissues. Skeletal muscle is the primary pharmacological target for AMPK activation studies and also represents a large tissue mass for distribution, which partly explains the relatively rapid plasma clearance. ^[7]

Intracellular pharmacokinetics differ substantially from plasma pharmacokinetics. Once ZMP accumulates inside cells, it is trapped by the negative charge of the phosphate group, which prevents passive efflux. This creates an intracellular ZMP concentration that persists well beyond plasma compound disappearance. Researchers designing time-course experiments should sample intracellular ZMP (or use AMPK Thr172 phosphorylation as a pharmacodynamic surrogate) rather than relying solely on plasma concentration to define the pharmacodynamically active window. ^[6]

Metabolism and Elimination

AICAR is eliminated primarily via renal excretion. The monophosphate form may be dephosphorylated by ectonucleotidases to the free riboside before filtration, or excreted intact as the nucleotide depending on species and renal capacity. Inside cells, ZMP is a substrate for ADSL (which converts it to SAICAR analog products) and can also be dephosphorylated by intracellular phosphatases. None of the identified metabolites are pharmacologically active in the sense of directly activating AMPK; metabolic clearance represents true termination of the ZMP signal. ^[3]

Drug-drug interactions in the research context are a consideration when AICAR is combined with other purine synthesis pathway inhibitors (methotrexate, pemetrexed), nucleoside transport inhibitors, or adenosine kinase inhibitors, as these can dramatically alter intracellular ZMP accumulation and create unpredicted pharmacodynamic effects. Researchers designing combination studies should account for these interactions explicitly.

Purity and Verification

What to Expect on a Certificate of Analysis

A legitimate AICAR CoA from a research-grade supplier should include the following minimum elements. First, an HPLC chromatogram with the main peak retention time, peak area percentage (target ≥98%), and identification of any detected impurity peaks. The HPLC method should specify the column type, mobile phase, and detection wavelength (typically UV at 268 nm, near the AICA chromophore absorption maximum). ^[6]

Second, a mass spectrometry result confirming molecular identity. For the monophosphate form (MW 338.21 g/mol), the expected [M+H]+ ion is m/z 339.2 and [M-H]- is m/z 337.2. The free riboside (MW 258.23 g/mol) gives [M+H]+ at m/z 259.2. Any CoA showing a mass inconsistent with the labeled form should be treated as a potential mislabeled or degraded product. ^[31]

Third, water content by Karl Fischer titration (lyophilized peptides commonly carry 5-15% residual water, which affects the true mass of active compound per vial). If the CoA reports anhydrous mass and the powder contains 8% water, the effective dose per milligram is lower than nominal - a practically significant correction for precise experimental work.

Fourth, a sterility certificate or statement of microbial limits if the compound is intended for in-vivo rodent studies. Endotoxin content (Limulus amebocyte lysate test, LAL) is particularly important for any in-vivo inflammatory endpoint study, since LPS contamination above 1 EU/mL can independently activate NF-kB pathways and confound AMPK/anti-inflammatory read-outs entirely.

Independent Verification Approaches

For laboratory managers who want to verify a CoA independently rather than relying solely on supplier data, several practical approaches are available. NMR spectroscopy (1H NMR at 400 MHz minimum) in D2O will show characteristic proton signatures for the AICA base (anomeric H1', ribose H2'-H5', and the exchangeable NH2 protons) that can be compared against published reference spectra. Chemical shift assignments for AICAR in D2O are well-documented in the literature. ^[6]

LC-MS/MS in multiple reaction monitoring (MRM) mode provides the most sensitive and specific identity confirmation and can simultaneously quantify major impurities at sub-0.1% levels. A research core facility with access to a triple quadrupole instrument can typically run an AICAR identity and purity screen for under $100 per sample. For longevity labs running extended in-vivo studies with AICAR as a key experimental variable, this investment in independent verification is well justified. See our guide to reading peptide CoAs for a step-by-step verification workflow.

Apollo Peptide Sciences Quality Standards

Apollo Peptide Sciences reports HPLC purity of ≥98% for their AICAR 50mg product, consistent with research-grade standards for nucleotide analogues. Their CoAs are available on request prior to purchase - a standard practice among reputable research peptide suppliers. Researchers should always request the batch-specific CoA (not a generic product CoA) and verify that the lot number on the CoA matches the vial received.

Dosage and Reconstitution

Reconstitution Protocol

AICAR is highly water-soluble, which simplifies reconstitution compared to more hydrophobic peptides or lipophilic small molecules. The recommended reconstitution solvent for most research applications is sterile water for injection (WFI) or phosphate-buffered saline (PBS, pH 7.4). A common approach for a 50 mg vial is to add 1 mL of sterile WFI to produce a 50 mg/mL (approximately 148 mM for the monophosphate form) concentrated stock solution.

For typical in-vitro cell culture experiments targeting 0.5-2 mM AICAR in culture media, this 148 mM stock requires a dilution factor of approximately 75-fold to 300-fold in culture medium. Working at these dilution factors ensures that the volume of AICAR stock added to a culture well is small enough to avoid osmotic or solvent effects on the cells. For cell culture work, it is common practice to prepare a secondary stock of 5-10 mM AICAR in PBS and add this directly to pre-warmed media to minimize temperature shock.

For reconstitution technique, solvent addition, and step-by-step guidance on preparation of injection-grade solutions for rodent studies, refer to the peptide reconstitution guide.

Literature-Reported Research Doses

The literature spans a wide dose range, and the appropriate research dose depends heavily on the experimental endpoint and model system. The following table summarizes doses from key published studies.

Worked Numerical Examples for In-Vitro Experiments

Example 1: Preparing 0.5 mM AICAR in a 24-well plate experiment. Starting with a 50 mg/mL stock (148 mM AICAR monophosphate, MW 338.21 g/mol) in sterile WFI. Target concentration in well: 0.5 mM. Total volume per well: 500 µL. Volume of stock needed = (0.5 mM / 148 mM) × 500 µL = 1.69 µL per well. This volume is pipettable but small; a 1:10 intermediate dilution (14.8 mM in PBS) would give 16.9 µL per well - a more precise and reproducible pipetting volume.

Example 2: Calculating dose for a 25g mouse study. A researcher replicating the Narkar et al. protocol at 500 mg/kg/day for a 25 g mouse would require: 500 mg/kg × 0.025 kg = 12.5 mg AICAR per mouse per day. Using a 50 mg/mL solution, this requires 250 µL per injection per mouse. This is within the acceptable range for IP injection in mice (typically up to 500 µL for a 25 g animal). A 50 mg vial reconstituted to 1 mL provides sufficient material for 4 daily injections of one 25 g mouse, or 1 injection per day for 4 mice at this dose.

Example 3: Calculating dose for a lower-dose metabolic study. Using the Winder et al. dose of 0.5 mmol/kg/day in a 250 g rat: 0.5 mmol × 338.21 g/mol / 1000 = 0.169 g/kg/day × 0.25 kg = 42.3 mg per rat per day. A 50 mg vial reconstituted in 1 mL (50 mg/mL) provides 1.18 mL of solution - nearly sufficient for one daily dose in one 250 g rat. Researchers planning multi-rat, multi-day experiments should calculate total compound requirements before ordering.

For detailed guidance on dosage mathematics, unit conversions, and scaling across species, refer to the dosage calculation guide.

Side Effects and Safety

Observed Adverse Effects in Animal Models

At doses used in standard metabolic research protocols (0.5 mmol/kg/day in rats), AICAR is generally well tolerated in rodents during short-term studies. Common findings at higher doses include transient hypoglycemia (a direct consequence of enhanced glucose uptake and suppressed hepatic glucose production) and transient hemodynamic changes reflecting AICAR's adenosine-releasing effects, including mild bradycardia and peripheral vasodilation. ^[5]

At the very high doses used in the Narkar et al. endurance protocol (500 mg/kg/day in mice), some animals showed weight loss and reduced food intake during the treatment period, consistent with the compound's anorexigenic effects downstream of AMPK activation in the hypothalamus. ^[11] Hematological effects have been reported in some studies: AICAR can inhibit the proliferation of rapidly dividing cells including erythroid precursors, potentially producing mild anemia with extended high-dose administration. This effect relates to purine synthesis disruption rather than AMPK activation per se. ^[15]

In-Vitro Pro-Apoptotic Effects

Multiple in-vitro studies across cancer cell lines have documented that AICAR induces cell cycle arrest (predominantly S-phase) and apoptosis at concentrations of 0.5-2 mM. ^[15] In chronic lymphocytic leukemia (CLL) cells, AICAR showed particularly potent pro-apoptotic effects, with IC50 values for cell death in the low-millimolar range. The mechanism is multi-factorial: AMPK-dependent mTORC1 suppression, direct purine synthesis inhibition causing nucleotide pool depletion, and indirect effects via ZMP on purine synthesis enzyme complexes. Researchers using AICAR in co-culture systems or in any experiment where cell survival of rapidly dividing cells is a variable should control carefully for these effects.

Interactions with Co-Administered Compounds

As noted in the mechanism section, combination with methotrexate or other antifolates dramatically potentiates AICAR accumulation and can produce synergistic cytotoxicity. Combination with compounds that activate AMPK through separate mechanisms (e.g., metformin via Complex I inhibition, resveratrol via SIRT1, berberine) may produce additive or supra-additive AMPK activation with unpredictable downstream consequences. This is relevant for longevity researchers who may be running multi-compound protocols.

Purine transport inhibitors (NBMPR/nitrobenzylmercaptopurine riboside) can block AICAR's cellular entry and completely abrogate ZMP formation, which has been used experimentally to confirm nucleoside transporter dependence of AICAR effects in specific cell types. ^[7]

WADA Prohibited List Status

AICAR appears on the World Anti-Doping Agency (WADA) Prohibited List under Section S4 (Hormone and Metabolic Modulators) as a metabolic modulator. ^[31] This is relevant for research institutions conducting studies with human athletic subjects; any detected AICAR or ZMP in urine or blood samples would constitute an analytical finding. For basic research laboratory use with rodent models or cell culture, this prohibition does not apply, but researchers should be aware of the compound's status when designing translational studies.

How It Compares

Comparative Analysis

AICAR's key advantage relative to direct AMPK activators (991, GSK621, MK-8722) is its substantial published literature base. Dozens of peer-reviewed studies using AICAR as the pharmacological tool have established a well-mapped experimental framework, including dose-response relationships, time-course data, and tissue-specific read-outs. Direct AMPK activators offer higher selectivity but are largely limited to in-vitro use due to sparse in-vivo pharmacokinetic characterization.

Relative to metformin, AICAR activates AMPK through a mechanistically distinct pathway (direct ZMP-gamma subunit interaction versus indirect AMP elevation via Complex I inhibition), which makes AICAR the preferred tool when researchers want to separate AMPK-specific effects from metformin's broader metabolic actions. AICAR's shorter plasma half-life compared to metformin also enables sharper temporal resolution in time-course experiments.

Relative to mTOR-targeted compounds like rapamycin, AICAR provides simultaneous AMPK activation and mTORC1 suppression through a single compound, which can be advantageous or confounding depending on experimental design. When the goal is isolating AMPK-specific signaling from mTOR-independent effects, a direct AMPK activator combined with rapamycin controls is methodologically cleaner than AICAR alone.

AICAR's partial CNS penetration positions it as a usable (though imperfect) tool for neurological AMPK studies. Researchers requiring robust CNS AMPK activation should consider direct intracerebroventricular administration protocols or in-vitro CNS cell culture approaches alongside systemic AICAR experiments. ^[17]

Open Research Questions

Lifespan Effects in Rodents

As noted in the study summaries above, formal randomized lifespan studies using AICAR as the sole intervention in mammalian models are sparse. The most compelling longevity data remains in short-lived invertebrates (C. elegans), and the translation from nematode AMPK biology to mammalian longevity is imperfect. The Interventions Testing Program (ITP), which systematically screens compounds for lifespan effects in outbred mice across three independent sites, has not yet published AICAR lifespan data. This is a meaningful gap. Researchers interested in longevity biology should treat current AICAR data as mechanistically suggestive rather than longevity-proven. ^[2]

AMPK Isoform Specificity

AICAR via ZMP activates all AMPK heterotrimers that contain gamma subunits with accessible Bateman domains, without meaningful isoform selectivity. Different alpha (alpha1 vs. alpha2), beta, and gamma isoform combinations have distinct tissue distributions and physiological roles. For example, alpha2-containing heterotrimers dominate in skeletal muscle and heart, while alpha1-containing forms predominate in lymphocytes and liver. ^[8] Whether the longevity-relevant AMPK signaling operates preferentially through specific heterotrimers is not yet established, and AICAR's non-selective activation profile is a limitation for mechanistic dissection. Development of isoform-selective AMPK activators is an active research priority.

Dose-Response Non-Linearity and High-Dose Concerns

The dose-response relationship for AICAR's beneficial metabolic effects is not monotonically positive. Several studies report that higher AICAR doses produce diminishing AMPK activation returns while pro-apoptotic and anti-proliferative effects increase disproportionately. ^[15] Identifying the dose range that maximizes beneficial AMPK signaling while minimizing off-target purine synthesis disruption is still an open question for most tissue types and experimental endpoints. This non-linearity complicates the design of in-vivo studies and may explain some inconsistencies in the literature.

Cognitive and Neuroprotective Mechanisms

The cognitive biology section of AICAR's literature is the least mature. The plausible mechanistic connections (AMPK-driven autophagy, neuroinflammation reduction, metabolic support for neurons) are well-established individually, but the integrated question of whether AICAR meaningfully improves cognitive function in aging rodent models - and through which mechanism - has not been systematically addressed with the same rigor as the metabolic endpoints. This is an active area for future study.

Where to Buy

Apollo Peptide Sciences is the vendor supplying the AICAR 50mg reviewed on this page. Their product listing, CoA availability, and current pricing can be found on the AICAR product page. Researchers evaluating vendors for any research peptide or nucleotide analogue purchase should consult the supplier selection guide for criteria on CoA standards, independent testing policies, and institutional compliance considerations.

For a full review of Apollo Peptide Sciences' quality documentation, shipping practices, and independent testing track record, see the Apollo Peptide Sciences supplier review. Pricing for the 50 mg AICAR vial is $60.00 at time of publication, which positions it competitively relative to other research-grade nucleotide analogue suppliers. Given the solubility and typical in-vitro use concentrations described above, a single 50 mg vial provides sufficient material for multiple independent cell culture experiments or a short-course rodent metabolic study at moderate doses.

FAQ